What is Tempus AI, Inc.'s market cap?

Tempus AI, Inc. (TEM) has a market capitalization of $8.5B and trades on NASDAQ.

What is Tempus AI, Inc.'s revenue and profitability?

Tempus AI, Inc. generated $1.4B in trailing twelve-month revenue with a net loss of $254.4M, representing a net margin of -17.8%, with free cash flow of -$279.6M. These figures are based on the Q2 2026 filing.

Who are Tempus AI, Inc.'s competitors?

Tempus AI, Inc.'s key competitors include Myriad Genetics, IQVIA, Guardant Health, and others. These companies compete in similar markets and product categories.

Who does Tempus AI, Inc. partner with?

Tempus AI, Inc.'s notable partners include AstraZeneca, GlaxoSmithKline, Recursion Pharmaceuticals, and others.

What subsidiaries does Tempus AI, Inc. have?

Tempus AI, Inc.'s subsidiaries include Ambry Genetics, Arterys, Paige, and others.

Where is Tempus AI, Inc. headquartered?

Tempus AI, Inc. is headquartered in United States of America and employs approximately 2,300 people. It has been publicly traded since 2024.

Tempus AI, Inc. (TEM) Stock Fundamentals & Financials

Tempus AI is a technology company that applies artificial intelligence to healthcare to enable precision medicine through its proprietary platform and operating system.

Market cap

$8.49B-11.7%

Revenue$1.4B+50.4%

Net income-$254.4M-27.4%

Free cash flow-$279.6M+23.9%

EPS (diluted)-$1.45+81.8%

Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

July 30, 2026

Revenue$382.5MBeat by $2.8M EPS-$0.04Beat by $0.10

Read the full report

Next report

Nov 3, 2026 (in 3 months)

Revenue estimate$409.9M

EPS estimate-$0.09

Financials

Q2 2026

Income statement

See full

Revenue$382.5M+21.6%

Operating income-$75.9M-22.9%

Net income$5.6M+113%

EPS (diluted)$0.03+112%

Balance sheet

See full

Cash & equivalents$599.6M+219%

Total debt$83.5M+51.1%

Total equity$444.9M+43.7%

Total assets$2.4B+45.6%

Cash flow

See full

Operating cash flow-$7.5M—

CapEx-$22.5M-400%

Free cash flow-$30.1M—

Valuation & ratios

Valuation

See full

Market cap$8.49B-11.7%

Enterprise value$7.97B-19.2%

P/S5.9×-4.6×

Profitability

See full

Operating margin-19.8%-3.3pp

Net margin-17.8%-2.4pp

FCF margin-19.5%—

Returns & leverage

See full

Return on equity-67.4%-16.0pp

Debt / equity0.2×0.0×

Current ratio3.3×+1.8×

Competitors

By market cap

Natera, Inc.$39.4B+106%

IQVIA$37.6B+20.1%

Guardant Health$21.4B+272%

Tempus AI, Inc.$8.5B-15.1%

GeneDx Holdings$2.1B-31.0%

Personalis, Inc.$1.4B+190%

Fulgent Genetics, Inc.$510.4M-19.8%

Myriad Genetics$303.2M-15.0%

By revenue growth

Tempus AI, Inc.+50.4%

Guardant Health+39.6%

Natera, Inc.+36.6%

GeneDx Holdings+34.1%

Fulgent Genetics, Inc.+9.5%

IQVIA+8.2%

Myriad Genetics-0.3%

Personalis, Inc.-24.7%

By net margin

IQVIA8.1%+0.2pp

Natera, Inc.-14.61%-3.2pp

GeneDx Holdings-17.58%+1.9pp

Tempus AI, Inc.-17.77%+3.2pp

Fulgent Genetics, Inc.-23.04%-9.1pp

Guardant Health-40.1%+13.7pp

Myriad Genetics-48.24%-36.0pp

Personalis, Inc.-148.11%-50.0pp

Profile

Tempus AI is a technology company that applies artificial intelligence to healthcare to enable precision medicine through its proprietary platform and operating system. The company integrates laboratory test results with clinical data to create Intelligent Diagnostics, providing personalized insights for therapy selection and treatment decisions. By amassing one of the world's largest libraries of clinical and molecular oncology data, the company serves both healthcare providers in clinical settings and life sciences companies in drug discovery and development.

Competitive position

Tempus maintains a leading position in precision medicine by operating at the intersection of high-throughput diagnostic sequencing and large-scale AI data analytics, creating a significant competitive moat through its multimodal database.

GeographiesUnited States

Customer segmentsHealthcare providers, Life sciences companies, Pharmaceutical companies, Research institutions

Business modelData licensing, Fee-for-service, Subscription SaaS, B2B

SuppliersSequencing hardware and reagents, Cloud computing infrastructure, Healthcare data from provider EHRs, Laboratory consumables

CustomersTreating physicians, Pharmaceutical R&D departments, Clinical trial managers, Health insurance payers

CountryUnited States of America

Listed2024

Employees2.3K

CEOEric Lefkofsky

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websitetempus.com

FilingsSEC EDGAR

FAQ

What is Tempus AI, Inc.'s market cap?: Tempus AI, Inc. (TEM) has a market capitalization of $8.5B and trades on NASDAQ.
What is Tempus AI, Inc.'s revenue and profitability?: Tempus AI, Inc. generated $1.4B in trailing twelve-month revenue with a net loss of $254.4M, representing a net margin of -17.8%, with free cash flow of -$279.6M. These figures are based on the Q2 2026 filing.
Who are Tempus AI, Inc.'s competitors?: Tempus AI, Inc.'s key competitors include Myriad Genetics, IQVIA, Guardant Health, and others. These companies compete in similar markets and product categories.
Who does Tempus AI, Inc. partner with?: Tempus AI, Inc.'s notable partners include AstraZeneca, GlaxoSmithKline, Recursion Pharmaceuticals, and others.
What subsidiaries does Tempus AI, Inc. have?: Tempus AI, Inc.'s subsidiaries include Ambry Genetics, Arterys, Paige, and others.
Where is Tempus AI, Inc. headquartered?: Tempus AI, Inc. is headquartered in United States of America and employs approximately 2,300 people. It has been publicly traded since 2024.

Ask your AI about Tempus AI, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude